MT2019-09: A randomized trial of low versus moderate exposure busulfan for infants with severe combined immunodeficiency (SCID) receiving TCR????+/CD19+ depleted transplantation: A Phase II study by the Primary Immune Deficiency Treatment Consortium (PID
|Effective start/end date||8/16/19 → 5/31/24|
- CHILDREN'S HOSPITAL LOS ANGELES
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.